JAMA Ophthalmology: Anxiety Disorders Topic Collection http://archopht.jamanetwork.com/ en-us Mon, 03 Dec 2012 00:00:00 GMT Tue, 01 Jan 2013 00:44:09 GMT Silverchair editor@archopht.jamanetwork.com webmaster@archopht.jamanetwork.com Evaluating Patient Discomfort, Anxiety, and Fear Before and After Ranibizumab Intravitreous Injection for Wet Age-Related Macular Degeneration http://archopht.jamanetwork.com/article.aspx?articleID=423686 Mon, 13 Jul 2009 00:00:00 GMT Chua P, Mitrut I, Armbrecht A, et al. <span class="paragraphSection">Ranibizumab (Lucentis) intravitreous injection (IVI) has emerged as a common treatment for wet age-related macular degeneration after 2 international, multicenter, controlled clinical trials, MARINA and ANCHOR, reported positive visual outcome compared with placebo and photodynamic therapy. Despite the therapeutic benefits of ranibizumab, repeated injections are required as often as every 4 weeks. We aimed to study the patients' perspective of treatment with ranibizumab, specifically pain, anxiety, and discomfort related to the ranibizumab IVI procedure. To our knowledge, there are no reports on this apart from one study investigating patient discomfort on receiving triamcinolone IVI.</span> 127 7 936 945 10.1001/archophthalmol.2009.139 http://archopht.jamanetwork.com/article.aspx?articleID=423686